Evidence map›Paper›PMID 28392419›Full record

ArticleAntiviral research2017

Early phase dynamics of traceable mCherry fluorescent protein-carrying HIV-1 infection in human peripheral blood mononuclear cells-transplanted NOD/SCID/Jak3

Nobuyo Higashi-Kuwata, Hiromi Ogata-Aoki, Shin-Ichiro Hattori, Hironori Hayashi, Matthew Danish, Manabu Aoki, Chiemi Shiotsu, Tatsuyoshi Kawamura, Hironobu Ihn, Hisataka Kobayashi and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Nobuyo Higashi-KuwataExperimental Retrovirology Section, Department of Refractory Viral Infection, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Departments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan.
Hiromi Ogata-AokiDepartments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan; Experimental Retrovirology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Shin-Ichiro HattoriExperimental Retrovirology Section, Department of Refractory Viral Infection, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Division of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Hironori HayashiExperimental Retrovirology Section, Department of Refractory Viral Infection, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Departments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan.
Matthew DanishDepartments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan.
Manabu AokiDepartments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan; Experimental Retrovirology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan.
Chiemi ShiotsuDepartment of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Tatsuyoshi KawamuraDepartment of Dermatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Hironobu IhnDepartment of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hisataka KobayashiMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Seiji OkadaDivision of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Hiroaki MitsuyaExperimental Retrovirology Section, Department of Refractory Viral Infection, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Departments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Japan; Experimental Retrovirology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: hmitsuya@helix.nih.gov.
Kumamoto University · JPNational Center for Global Health and Medicine · JPNational Institutes of Health · USUniversity of Yamanashi · JP

Funding

Development of Antiviral Therapy of HIV-1 InfectionZIASC006738 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI MITSUYA, HIROAKI · 2009 to 2025
$10.0M
HIV TRIALSZ01SC006738 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI MITSUYA, HIROAKI · 1996 to 2008
$1.4M
Intramural NIH HHS Z01 SC006738
6 · The paper itself

Abstract

We attempted to elucidate early-phase dynamics of HIV-1 infection using replication-competent, red-fluorescent-protein (mCherry)-labeled HIV-1

Indexed as

AnimalsDisease Models, AnimalGenes, ReporterHIV-1HIV InfectionsJanus Kinase 3Leukocytes, MononuclearLuminescent ProteinsLymph NodesMiceMice, Inbred NODMice, SCIDRed Fluorescent ProteinStaining and LabelingJak3 protein, mouseJanus Kinase 3Luminescent ProteinsRed Fluorescent ProteinCell-associated HIV infectionEarly phase dynamicsHIV propagationIn vivo imaging

Identifiers

PMID28392419
PMCPMC7900919
OpenAlexW2604196148

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.